www.bloomberg.com
Novo Nordisk’s CEO stated that their upcoming obesity pill will expand market reach by targeting the vast population of patients who have not yet taken GLP-1 drugs. By shifting away from injectable forms previously dominated by competitors like Eli Lilly, this new oral medication aims to capture a broader patient base and increase accessibility to obesity treatment. The move represents a strategic expansion beyond current GLP-1 users, potentially opening treatment options to millions of new patients who may have been hesitant about injections.
Read More
